BLOG

3 takeaways from the HIMSS16 annual conference

ZappRx was among the 42,000 attendees at the 2016 HIMSS conference February 29 through March 4 in Las Vegas. This...

Free ebook: What Ails Specialty Drug Prescribing?

Filter By Topic

specialty drugs (9)
Biotech / biopharma (7)
speed to therapy (6)
Patients and caregivers (5)
specialty pharmacy (5)
digital health (4)
Multiple Sclerosis (MS) (3)
manufacturers (3)
pulmonary hypertension (3)
specialty medications (3)
Blog (2)
PHPN (2)
big data (2)
biosimilars (2)
fulfillment process (2)
podcast (2)
prescription drug costs (2)
rare disease day (2)
rheumatoid arthritis (2)
workflow (2)
Awards (1)
Crohn’s Disease (1)
Culture (1)
HIMSS16 (1)
Interview (1)
Investors (1)
JPMorgan (1)
PAH (1)
Pharmacies (1)
SCOTUS (1)
bernie sanders (1)
brand adoption (1)
cost (1)
donald trump (1)
epilepsy (1)
hillary clinton (1)
hubs (1)
pharmacists (1)
prescription drug cost (1)
presidential election (1)
prior authorization (1)
psoriatic arthritis (1)
startups (1)
ted cruz (1)
value-based care (1)

Past Posts

June 2016 (5)
January 2016 (3)
February 2016 (3)
March 2016 (3)
April 2016 (3)
November 2015 (2)
July 2016 (2)
July 2017 (2)
December 2015 (1)
May 2016 (1)
October 2016 (1)
November 2016 (1)
January 2017 (1)
April 2017 (1)
June 2017 (1)
August 2017 (1)
September 2017 (1)
October 2017 (1)
November 2017 (1)
December 2017 (1)
November 2018 (1)

About ZappRx^®, Inc.

ZappRx is a digital health company offering a prescription and prior authorization (“PA”) platform; our goal is to streamline and increase efficiencies in the way specialty medications reach patients. We provide a secure, collaborative online platform that allows patients, physicians, and pharmacists to work together to improve patients’ access to treatment and deliver medicine faster.

Solutions

Healthcare Providers
Specialty Pharmacies
Biopharma
Security standards

Company

Leadership
Careers

News & Events

Blog
Press Releases
Media Coverage
Events
Awards

ZappRx and the "Z" logo are registered trademarks of ZappRx, Inc.